Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

Will Lead Business Development Activities After 14 Years as Executive Director of Maryland Stem Cell Research Fund

MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.

Dr. Gincel brings over 20 years of leadership experience overseeing development and commercialization of regenerative medicines, including cell and gene therapies, as well as establishing public-private collaborations and corporate partnerships. Previously, he served as Vice President of University Partnerships and a member of the Executive Leadership Team at the Maryland Technology Development Corporation (TEDCO), where he oversaw programs to accelerate the commercialization of technologies from federal, state, and private Maryland research institutions. Additionally, he served as Executive Director at the Maryland Stem Cell Research Fund (MSCRF), where he managed over $150+ million in stem cell research funding. During his tenure, he helped create and support more than 55 technology startup companies with over $120 million of follow-on funding and numerous successful exits. Dr. Gincel received both his Ph.D. (2003) and his B.Sc. (1996) from Ben-Gurion University in Israel. He currently serves on numerous boards supporting companies and economic development.

Geoff Green, CEO of Longeveron, stated, “Dan’s scientific and entrepreneurial background will contribute significantly to our organization as we continue to advance our mission to develop and launch new cell therapies for aging-related chronic disease and life-threatening conditions. Having a widely respected entrepreneur of Dan’s caliber will also assist us in evaluating strategic collaborations, both in the U.S. and abroad, as well as in-licensing new technologies to further progress our LOMECEL-B cell-based therapy platform and overall product pipeline.”

“I have known and collaborated with the outstanding Longeveron team for many years as they have advanced Lomecel-B through trials for Aging Frailty, Hypoplastic Left Heart Syndrome and Acute Respiratory Distress Syndrome and I look forward to bringing to bear my experience and insights in cell therapy to creating value at the company and working with these exciting product candidates,” stated Dr. Gincel.